Lexicon Pharmaceuticals(LXRX)
$1.53-0.14 (-8.38%)
LXRX
Lexicon Pharmaceuticals financials statements
$1.53
At close:-0.14 (-8.38%)
Want to see LXRX full AI Analyst Report?
Lexicon Pharmaceuticals (LXRX) Ratios
1,836 Followers
Lexicon Pharmaceuticals Ratios
LXRX's free cash flow for Q3 2026 was $-8.08M. For the 2026 fiscal year, LXRX's free cash flow was increased by $0.00 and operating cash flow was $-8.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.88 | 5.44 | 5.60 | 6.08 | 4.02 |
| Quick Ratio | 4.87 | 5.44 | 5.58 | 6.08 | 4.02 |
| Cash Ratio | 1.64 | 1.47 | 0.71 | 2.00 | 2.90 |
| Solvency Ratio | -0.64 | -1.31 | -1.30 | -1.32 | -3.75 |
| Operating Cash Flow Ratio | -3.25 | -3.95 | -5.13 | -3.83 | -3.93 |
| Short-Term Operating Cash Flow Coverage | -10.88 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 24.45M | $ 93.72M | $ 40.23M | $ 63.69M | $ 65.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 0.36 | 0.46 | 0.28 | 0.02 |
| Debt-to-Equity Ratio | 0.58 | 0.74 | 1.14 | 0.47 | 0.02 |
| Debt-to-Capital Ratio | 0.37 | 0.43 | 0.53 | 0.32 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.31 | 0.41 | 0.52 | 0.29 | 0.00 |
| Financial Leverage Ratio | 1.72 | 2.04 | 2.46 | 1.66 | 1.21 |
| Debt Service Coverage Ratio | -2.84 | -11.83 | -12.96 | -35.98 | -108.23 |
| Interest Coverage Ratio | -5.87 | -12.65 | -13.11 | -36.24 | -108.59 |
| Debt to Market Cap | 0.13 | 0.42 | 0.29 | 0.15 | 0.00 |
| Interest Debt Per Share | 0.19 | 0.39 | 0.54 | 0.35 | 0.02 |
| Net Debt to EBITDA | -0.67 | -0.23 | -0.49 | -0.09 | 0.71 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.45% | 98.02% | -4798.01% | -37681.29% | -18371.81% |
| EBIT Margin | -84.34% | -594.65% | -14145.35% | -72273.38% | -29224.83% |
| EBITDA Margin | -83.09% | -592.93% | -14099.34% | -71966.19% | -29126.85% |
| Operating Profit Margin | -98.21% | -634.20% | -14264.95% | -72489.21% | -29224.83% |
| Pretax Profit Margin | -101.08% | -644.78% | -14710.88% | -73341.01% | -29448.99% |
| Net Profit Margin | -101.08% | -644.78% | -14710.88% | -73341.01% | -29448.99% |
| Continuous Operations Profit Margin | -101.08% | -644.78% | -14710.88% | -73341.01% | -29448.99% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 102.92% | 101.67% | 103.13% | 101.18% | 100.77% |
| Return on Assets (ROA) | -27.21% | -67.15% | -77.20% | -52.47% | -64.10% |
| Return on Equity (ROE) | -46.81% | -137.31% | -190.23% | -87.04% | -77.26% |
| Return on Capital Employed (ROCE) | -29.80% | -77.86% | -86.79% | -58.88% | -75.87% |
| Return on Invested Capital (ROIC) | -28.71% | -77.50% | -86.23% | -58.44% | -75.16% |
| Return on Tangible Assets | -35.84% | -78.94% | -95.80% | -68.07% | -95.01% |
| Earnings Yield | -12.06% | -84.79% | -52.35% | -32.20% | -15.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 20.89 | 8.95 | 1.19 | 4.96 | 21.29 |
| Payables Turnover | 0.09 | 0.04 | 4.10 | 5.05 | 6.01 |
| Inventory Turnover | 0.98 | 2.67 | 154.78 | 0.00 | 0.00 |
| Fixed Asset Turnover | 5.42 | 4.25 | 0.16 | 0.02 | 0.09 |
| Asset Turnover | 0.27 | 0.10 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.35 | 0.18 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3715.12 | -8592.41 | 219.49 | 1.28 | -43.54 |
| Days of Sales Outstanding | 17.47 | 40.79 | 306.19 | 73.53 | 17.15 |
| Days of Inventory Outstanding | 374.32 | 136.88 | 2.36 | 0.00 | 0.00 |
| Days of Payables Outstanding | 4106.92 | 8770.07 | 89.06 | 72.25 | 60.69 |
| Operating Cycle | 391.80 | 177.66 | 308.55 | 73.53 | 17.15 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.19 | -0.56 | -0.73 | -0.54 | -0.60 |
| Free Cash Flow Per Share | -0.19 | -0.56 | -0.73 | -0.54 | -0.61 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -173.40 | -344.46 | -67.01 | -71.27 |
| Capital Expenditure Coverage Ratio | 0.00 | -173.40 | -344.46 | -67.01 | -71.27 |
| Operating Cash Flow Coverage Ratio | -1.09 | -1.65 | -1.53 | -1.61 | -38.18 |
| Operating Cash Flow to Sales Ratio | -1.36 | -5.75 | -134.47 | -639.22 | -292.00 |
| Free Cash Flow Yield | -16.25% | -76.08% | -47.99% | -28.49% | -15.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.21 | -1.17 | -1.91 | -3.11 | -6.54 |
| Price-to-Sales (P/S) Ratio | 8.38 | 7.60 | 281.00 | 2277.34 | 1925.73 |
| Price-to-Book (P/B) Ratio | 3.88 | 1.62 | 3.63 | 2.70 | 5.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.15 | -1.31 | -2.08 | -3.51 | -6.50 |
| Price-to-Operating Cash Flow Ratio | -6.15 | -1.32 | -2.09 | -3.56 | -6.59 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | 0.06 | -0.07 | -1.89 | 2.06 |
| Enterprise Value Multiple | -10.76 | -1.51 | -2.49 | -3.25 | -5.90 |
| Enterprise Value | 445.42M | 278.08M | 421.93M | 325.50M | 512.08M |
| EV to EBITDA | -10.76 | -1.51 | -2.49 | -3.25 | -5.90 |
| EV to Sales | 8.94 | 8.95 | 350.44 | 2341.72 | 1718.40 |
| EV to Free Cash Flow | -6.56 | -1.55 | -2.60 | -3.61 | -5.80 |
| EV to Operating Cash Flow | -6.56 | -1.56 | -2.61 | -3.66 | -5.88 |
| Tangible Book Value Per Share | 0.17 | 0.32 | 0.22 | 0.44 | 0.47 |
| Shareholders’ Equity Per Share | 0.30 | 0.46 | 0.42 | 0.71 | 0.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.14 | 0.10 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -0.14 | -0.63 | -0.80 | -0.62 | -0.60 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.20 | 1.08 | 1.04 | 1.01 | 1.01 |
| Research & Development to Revenue | 1.23 | 2.72 | 48.91 | 379.97 | 184.72 |
| SG&A to Revenue | 0.75 | 4.24 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.25 | 0.43 | 11.91 | 82.88 | 35.49 |
| Income Quality | 1.35 | 0.89 | 0.91 | 0.87 | 0.99 |
Currency in USD
